Secondary endpoints
DISORDER, RECURRENCE, ADVERSE EVENTS, COVID-19 INFECTION, REACTOGENICITY
Data on vaccine-related AEs are shown in Reactogenicity adverse events up to 7 days after homologous and heterologous boosting in autologous hematopoietic stem cell transplant recipients.At a mean follow-up of 171.95 (95% CI: 157.36 - 186.53) days after the booster dose, 2 of the 31 (6%) heterologous and 4 of the 30 (13%) homologous arm patients developed PCR-documented COVID-19 infections presented with mild respiratory symptoms; nonetheless, only one patient, from the homologous arm, was hospitalized. Through this, no recurrence of the underlying disorder appeared.